On December 11, 2020, Chinese paper
Global Times reported that its border defense troops near the Line of Actual Control (LAC) with India received “Iron Man’ type exoskeleton suits to conduct tasks such as supply delivery, patrol and sentry duties in high altitude environments.
Les gardes-frontière de l armée chinoise en région de Ngari, au #Tibet, commencent à s équiper de l exosquelette passif pour les missions de ravitaillement.
L Institut 208 du groupe NORINCO a quant à lui reçu en Décembre une 2ème commande de l armée pour les troupes de montagne. pic.twitter.com/bPA3fxedTT
Several soldiers attached to the People’s Liberation Army (PLA) Xinjiang Military Command carried food and water supplies weighing 20 kg to an undisclosed location. Due to lack of oxygen in high altitude regions, goods feel much heavier than their actual weight, while human stamina decreases with corresponding increase in elevation. As such the weight of the backpacks are transferred
ICMM Beijing symposium on military medicine held
2020-12-15 17:24
By Wang Di and Shao Longfei
BEIJING, Dec. 15 The International Committee on Military Medicine (ICMM) Beijing Symposium hosted by the Academy of Military Medical Sciences under the PLA Academy of Military Sciences was held in early December.
Over 80 representatives from home and abroad including Major General Andreas Stettbacher, Chairman of the ICMM , Major General (ret.) Geert Laire, Secretary-General of the ICMM, Jacques Pellet, personal envoy of the president of the International Committee of the Red Cross (ICRC) for China , as well as officials from the Health Bureau of the Logistic Support Department of China’s Central Military Commission (CMC) and the Academy of Military Medical Sciences participated in the symposium in the form of online and on-site attendance.
Covid Vaccine Developed by China’s Zhifei Enters Phase III Trials in Uzbekistan Xu Wei Covid Vaccine Developed by China’s Zhifei Enters Phase III Trials in Uzbekistan
(Yicai Global) Dec. 11 A Covid-19 vaccine developed by Chongqing Zhifei Biological Products began Phase III human trials in Uzbekistan yesterday, making the Central Asian country the first to kick off the shot’s global third-stage tests.
Some 5,000 volunteers will take part in testing the recombinant vaccine, which was developed by Anhui Zhifei Longcom Biopharmaceutical, a wholly owned subsidiary of Zhifei Biological, and the Institute of Microbiology under the Chinese Academy of Sciences.